

Prevention of severe RSV disease in babies

RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. We offer an antibody developed against the RS virus called nirsevimab in our hospitals to infants and children who are at risk of severe RSV infection.


The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV. Immunization with nirsevimab is voluntary and free of charge for families.

Nirsevimab is offered to

- Infants born at HUS maternity hospitals from September 4, 2025.
- Children under the age of 12 months who belong to high-risk groups for severe RSV infection when they have an appointment in specialized healthcare at HUS New Children's Hospital, Jorvi Hospital, or Hyvinkää Hospital.

At-risk groups:

- Heart defect or heart disease for which surgery is planned or regular medication is needed.
- Severe immunodeficiency according to the attending physician
- Lung disease in a premature infant, i.e. bronchopulmonary dysplasia, for which some form of respiratory support treatment has been needed in the past 6 months or similar severe chronic pulmonary disease
- Down syndrome



More information: hus.fi/en/rsv